Phase II Study of Gemcitabine and Bevacizumab As First-Line Treatment in Taxane-Pretreated, HER2-Negative, Locally Recurrent or Metastatic Breast Cancer
Titel:
Phase II Study of Gemcitabine and Bevacizumab As First-Line Treatment in Taxane-Pretreated, HER2-Negative, Locally Recurrent or Metastatic Breast Cancer
Auteur:
Borson, Rachel Harker, Graydon Reeves, James Beck, Thaddeus Hager, Steven Horvath, William Jones, Michael Tillinghast, Guy Arrowsmith, Edward Harrer, Grant Kudrik, Fred J. Malamud, Stephen C. Bromund, Jane Zeigler, Haoyue Tai, Datchen Fritz Kornberg, Lori J. Obasaju, Coleman Orlando, Mauro Yardley, Denise A.